October 17, 2007 - Positron Corp. introduced its new dedicated-Cardiac PET system, Attrius, at the annual meeting of the American Society of Nuclear cardiology, for which it expects to receive 510k FDA approval in spring of 2008 in time for proposed cardiac PET reimbursement increase on Jan 1, 2008.
The new PET system for molecular imaging, which primarily targets cardiology, is less than $600,000. Positron intends to be the first company to offer absolute coronary flow reserve calculations developed by K. Lance Gould, M.D., who is considered the founder of Cardiac PET combined with the discovery of flow reserve in human studies.
“We will be the only company that is focused on bringing to market an affordable dedicated cardiac PET scanner with superior technology and disease focused software. We anticipate receiving our 510k FDA approval in spring of 2008," said Positron President Joseph Oliverio.
For more information: www.positron.com and www.is2medical.com